This webinar is intended for the pharmaceutical industry and associated service providers. It will provide pharmacovigilance and quality assurance departments with an overview of regulatory requirements and expectations for Good Pharmacovigilance Practice audit programmes, with a focus on auditing of activities internal to an organisation as well as those contracted out to service providers and commercial partners, such as distributors and licence partners.
Module IV of European Guideline on Good Pharmacovigilance Practices takes basic auditing principles and describes their application to the pharmacovigilance environment. Whilst the application legislation originates in Europe, the requirement is for a global audit programme that considers all activities and all stakeholders resulting in a resource-intensive and complex activity. All pharmaceutical companies and service provides must ensure they have an audit programme in place that meets agency expectations. The programme should be risk-based, ensuring that areas of high risk are identified and targeted. Finally, the audit programme should not only meet regulatory requirements, but also help the organisation in identifying areas of weakness and supporting the continued evolution of the pharmacovigilance system.
Why Should You Attend:
The introduction of Good Pharmacovigilance Practices in Europe emphasized the need for the pharmaceutical industry to have robust auditing of their pharmacovigilance systems across their audit universe, i.e. activities conducted by global departments, affiliates, service providers, distributors, etc. Subsequent inspections by European regulatory agencies had and continue to have frequent critical and major findings relating to audit practices, showing the need for the industry to continue to develop this area. This webinar will consider regulatory obligations and discuss practical implementation of the audit lifecycle, from risk assessment to scheduling to conduct of audits.Module IV of European Guideline on Good Pharmacovigilance Practices takes basic auditing principles and describes their application to the pharmacovigilance environment. Whilst the application legislation originates in Europe, the requirement is for a global audit programme that considers all activities and all stakeholders resulting in a resource-intensive and complex activity. All pharmaceutical companies and service provides must ensure they have an audit programme in place that meets agency expectations. The programme should be risk-based, ensuring that areas of high risk are identified and targeted. Finally, the audit programme should not only meet regulatory requirements, but also help the organisation in identifying areas of weakness and supporting the continued evolution of the pharmacovigilance system.
Areas Covered in the Webinar:
- European Guideline on Good Pharmacovigilance Practices: Modules I and IV
- Risk assessment of pharmacovigilance systems
- Scheduling of pharmacovigilance audits
- Conduct of pharmacovigilance audits - global departments, affiliates, service providers and commercial partners
Who Will Benefit:
- Quality assurance departments
- Pharmacovigilance departments
- Pharmacovigilance auditors
- Free Materials:
- Reference documents
- Rule documents or guidance
- Checklist
- SOP template
- Easy fill in forms
- Articles
Course Provider
Miranda Dollen,